Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
Benitec Biopharma reported fiscal 2026 (ended June 30, 2026) results with a net loss of $45.5 million, or $0.98 per basic and diluted share, versus a $37.9 million loss, or $1.05 per share, in fiscal 2025. Total expenses rose to $51.2 million from $41.8 million, led by R&D of $23.4 million and G&A of $27.8 million tied to the BB-301 program. The company ended the year with $180.0 million in cash and cash equivalents, nearly double the $97.7 million held a year earlier, and describes itself as well-capitalized.
Key figures
- Drug Name
- BB-301
- Phase Of Trial
- Phase 1b/2a
- Cash
- 179972000
- Net loss
- 45546000
- Ga expenses
- 27804000
- Rd expenses
- 23388000
- Cash prior year
- 97744000
- Shares outstanding
- 34416834
- Interest income net
- 5569000
- Net loss prior year
- 37917000
- Pivotal trial start
- mid-2027
- Cohort2 patients dosed
- 3
- Esgct data presentation
- October 27-30, 2026
- Total operating expenses
- 51192000
- Shares outstanding prior year
- 26250469
- Total operating expenses prior year
- 41765000
- Cohort1 patients completed 12mo followup
- 6
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.